Stewart T. Chang

TL;DR: Covasim as discussed by the authors is an agent-based simulation model developed to examine epidemic dynamics and inform policy decisions in more than a dozen countries in Africa, Asia-Pacific, Europe, and North America.

TL;DR: Estimates suggest that earlier eligibility for antiretroviral therapy is very cost effective in low-income and middle-income settings, although these estimates should be revisited when more data become available.

TL;DR: Major reductions in tuberculosis burden seem possible with current interventions, however, additional interventions, adapted to country-specific tuberculosis epidemiology and health systems, are needed to reach the post-2015 End TB Strategy targets at country level.

TL;DR: In general, expansion of tuberculosis services substantially reduced patient-incurred costs and, in India and China, produced net cost savings for most interventions under a societal perspective, and most intervention approaches seemed highly cost-effective.

TL;DR: In this article, the authors describe updates to the methodology of Covasim (COVID-19 Agent-based Simulator) to account for immune trajectories over time, correlates of protection, co-circulation of different variants and the rollout of multiple vaccines.